[
    [
        {
            "time": "",
            "original_text": "沪深港通资金医药股流向数据库",
            "features": {
                "keywords": [
                    "沪深港通",
                    "资金",
                    "医药股",
                    "流向",
                    "数据库"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沪深港通资金医药股流向数据库",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：新冠小分子药MOLNUPIRAVIR进展迅速 关注相关产业投资机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "新冠",
                    "小分子药",
                    "MOLNUPIRAVIR",
                    "进展",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：新冠小分子药MOLNUPIRAVIR进展迅速 关注相关产业投资机会",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "新冠系列专题深度(二)：Q4窗口期 看好新冠口服药物及其CDMO投资机遇",
            "features": {
                "keywords": [
                    "新冠",
                    "系列专题",
                    "Q4",
                    "窗口期",
                    "口服药物",
                    "CDMO",
                    "投资机遇"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠系列专题深度(二)：Q4窗口期 看好新冠口服药物及其CDMO投资机遇",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]